Publications by authors named "Gilead Raday"
Article Synopsis
- Patients with severe COVID-19 pneumonia have limited treatment options, and opaganib is an oral medication being researched to help those hospitalized.
- A clinical trial conducted in 57 locations from August 2020 to July 2021 compared opaganib to a placebo over 14 days, focusing on whether patients could stop needing supplemental oxygen by day 14.
- Although the primary results showed no significant general benefit, post-hoc analysis indicated that patients with low oxygen levels at baseline may experience better outcomes with opaganib, including reduced intubation rates and lower mortality, suggesting the need for further studies in this specific group.
Objectives: Slow-growing nontuberculous mycobacteria (NTMs) are highly prevalent and routinely cause opportunistic intracellular infectious disease in immunocompromised hosts.
Methods: The activity of the triple combination of antibiotics, clarithromycin (CLR), rifabutin (RFB), and clofazimine (CFZ), was evaluated and compared with the activity of single antibiotics as well as with double combinations in an in vitro biofilm assay and an in vivo murine model of subsp. () lung infection.
Article Synopsis
- Opaganib, an oral medication that inhibits sphingosine kinase-2 and has antiviral and anti-inflammatory effects, was tested for its potential benefits in treating moderate to severe COVID-19 pneumonia, particularly focusing on safety and its impact on oxygen needs and hospital stay duration.
- The study was a Phase 2a, randomized, double-blind, placebo-controlled trial involving 42 patients in the US, where 23 received opaganib and 19 received a placebo for up to 14 days.
- Results showed no major safety issues, with lower adverse events in the opaganib group, and initial evidence suggested opaganib may help reduce oxygen requirements and potentially allow for quicker hospital discharge, warranting further research.
Introduction: Previous, small studies have suggested that ondansetron has beneficial effects in diarrhea-predominant irritable bowel syndrome (IBS-D). This randomized, double-blind study evaluated the efficacy and safety of daily 12 mg RHB-102, an investigational bimodal release ondansetron tablet, in IBS-D.
Methods: Men and women with IBS-D by the Rome III criteria, Bristol Stool Scale ≥6 on 2 or more days weekly, and average daily worst pain intensity ≥3/10 were randomized 60:40 to RHB-102 or placebo once daily for 8 weeks.
Importance: Vomiting resulting from acute gastroenteritis is commonly treated with intravenous antiemetics in acute care settings. If oral treatment were beneficial, patients might not need intravenous administered hydration or medication. Furthermore, a long-acting treatment could provide sustained relief from nausea and vomiting.
View Article and Find Full Text PDF